<DOC>
	<DOC>NCT00510484</DOC>
	<brief_summary>This study will assess the effect of pancrelipase delayed release 24,000 unit capsules on fat and nitrogen absorption in subjects with PEI due to Cystic Fibrosis.</brief_summary>
	<brief_title>Study Investigating a Delayed-Release Pancrelipase in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>Confirmed CF diagnosis by two positive chloride sweat tests or gene analysis Confirmed PEI by historical CFA &lt; 70% without supplementation or current or historical fecal elastase &lt; 50Âµg/g stool (within the last 12 months) Subjects of 12 years or older Currently receiving treatment with a commercially available pancreatic enzyme product on a stable dose for more than 3 months Clinically stable condition without evidence of acute respiratory disease or any other acute condition Females of childbearing potential must agree to continue using a medically acceptable method of birth control Ileus or acute abdomen History of fibrosing colonopathy History of distal ileal obstruction syndrome within 6 months of enrollment Use of an immunosuppressive drug Any type of malignancy involving the digestive tract in the last 5 years Known infection with HIV</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Pancreatic exocrine insufficiency</keyword>
	<keyword>Cystic Fibrosis</keyword>
</DOC>